Welcome to our dedicated page for THERIVA BIOLOGICS news (Ticker: TOVX), a resource for investors and traders seeking the latest updates and insights on THERIVA BIOLOGICS stock.
Theriva Biologics, Inc. develops therapeutics for cancer and related diseases as a diversified clinical-stage biotechnology company. Its subsidiary, Theriva Biologics, S.L., is developing an oncolytic adenovirus platform for intravenous, intravitreal and antitumoral delivery. The company’s lead candidate, VCN-01, is designed to replicate selectively within tumor cells and degrade the tumor stroma barrier associated with cancer treatment resistance.
Recurring Theriva Biologics news includes VCN-01 clinical data in metastatic pancreatic ductal adenocarcinoma and retinoblastoma, regulatory interactions with U.S. and European agencies, medical-conference presentations, and operational financial results. Coverage also includes SYN-004, or ribaxamase, for gastrointestinal degradation of certain IV beta-lactam antibiotics, and the licensed SYN-020 recombinant intestinal alkaline phosphatase program.
Theriva Biologics (NYSE American: TOVX) has rescheduled its conference call to November 11, 2022, at 8:30 a.m. ET to discuss Q3 2022 financial results and corporate updates. The original date was set for November 10. Participants can join via phone or access the call through the company's website. Theriva is focused on developing therapeutics for cancer treatment, with key products including VCN-01, SYN-004, and SYN-020, aimed at improving patient outcomes in high unmet need areas.
Theriva Biologics (TOVX) will host a conference call on November 10, 2022, at 8:30 a.m. ET, to discuss its financial results for Q3 2022, ending September 30. The call will provide a corporate update, with live participation available via phone or online. The company specializes in developing therapeutics for cancer and related diseases, including innovative treatments like VCN-01, SYN-004, and SYN-020. For further details, visit their website.
Theriva Biologics (TOVX) announced the dosing of the first patient in Cohort 2 of its ongoing Phase 1b/2a clinical trial for SYN-004, aimed at preventing acute graft-versus-host disease (aGVHD) in allogeneic hematopoietic cell transplant (HCT) recipients. Following a positive safety review of Cohort 1 by an independent committee, the trial will assess SYN-004’s safety and pharmacokinetics while evaluating its protective effects on the gut microbiome. The trial is expected to enroll up to 36 participants, advancing therapeutic options for patients with hematologic cancers.
Theriva Biologics (NYSE American: TOVX) announced a KOL webinar on November 7, 2022, at 11 a.m. ET, featuring experts Michael Aaron Morse, M.D., and Arsen Osipov, M.D. The discussion will focus on the oncolytic virus landscape and data supporting the Company’s novel oncolytic adenovirus platform for treating cancers with high unmet needs, specifically pancreatic ductal adenocarcinoma (PDAC). The upcoming Phase 2 trial, VIRAGE, will evaluate VCN-01 combined with standard chemotherapy. A live Q&A will follow the presentation.
Theriva Biologics (TOVX) announced an oral presentation highlighting the encouraging biological activity of VCN-01 in combination with durvalumab at the 14th International Oncolytic Virotherapy Conference in Japan. The Phase 1 study focuses on patients with recurrent/metastatic squamous cell carcinoma of the head and neck (R/M HNSCC). The presentation, scheduled for October 25, 2022, will be delivered by COO Frank Tufaro. This research may support further development of VCN-01 as a viable treatment option in oncology.
Theriva Biologics, formerly known as Synthetic Biologics, Inc. (NYSE American: TOVX), announced a rebranding to reflect its focus on developing innovative oncolytic viruses for cancer treatment. The new branding will be visible with the stock trading under the ticker symbol TOVX starting October 13, 2022. The company highlighted its lead clinical program, VCN-01, aimed at improving tumor treatment, alongside the preclinical program VCN-11. Theriva aims to significantly impact patients with high unmet needs through its advanced therapies, reinforcing its commitment to addressing challenging cancers.